Mangiferin inhibits renal urate reabsorption by modulating urate transporters in experimental hyperuricemia

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 10, 2015, Pages 1591-1598

  Yang, Hua ^a   Gao, Lihui ^a   Niu, Yanfen ^a   Zhou, Yuanfang ^a   Lin, Hua ^a   Jiang, Jing ^b   Kong, Xiangfu ^c   Liu, Xu ^a   Li, Ling ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b KUNMING INSTITUTE OF PRECIOUS METALS   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hyperuricemia; Mangiferin; Renal urate transporter; Urate reabsorption; Uricosuric effect

Indexed keywords

GLUCOSE TRANSPORTER 9; MANGIFERIN; MEMBRANE PROTEIN; MESSENGER RNA; ORGANIC ANION TRANSPORTER 10; OTERACIL POTASSIUM; PDZ DOMAIN CONTAINING PROTEIN 1; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; URATE; URATE ANION TRANSPORTER 1; URATE TRANSPORTER; URIC ACID; ANION TRANSPORT PROTEIN; CARRIER PROTEIN; GLUCOSE TRANSPORTER; GLUT6 PROTEIN, RAT; OTERACIL; PDZK1 PROTEIN, RAT; URAT1 PROTEIN, RAT; URICOSURIC AGENT; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; HYPERURICEMIA; IN VIVO STUDY; KIDNEY TUBULE ABSORPTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; KIDNEY; MALE; METABOLISM; SPRAGUE DAWLEY RAT; URINE;

ANIMALS; ANION TRANSPORT PROTEINS; CARRIER PROTEINS; HYPERURICEMIA; KIDNEY; MALE; MICE; MONOSACCHARIDE TRANSPORT PROTEINS; OXONIC ACID; RATS, SPRAGUE-DAWLEY; URIC ACID; URICOSURIC AGENTS; XANTHONES;

EID: 84946906996     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b15-00402     Document Type: Article

References (31)

1. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol., 9, 13-23 (2013).
2. Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv. Ther., 32, 31-41 (2015).
3. Lee JM, Kim HC, Cho HM, Oh SM, Choi DP, Suh I. Association between serum uric acid level and metabolic syndrome. J. Prev. Med. Public Health, 45, 181-187 (2012).
4. Zoccali C, Mallamaci F. Uric acid, hypertension, and cardiovascular and renal complications. Curr. Hypertens. Rep., 15, 531-537 (2013).
5. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature, 417, 447-452 (2002).
6. Dinour D, Gray NK, Campbell S, Shu X, Sawyer L, Richardson W, Rechavi G, Amariglio N, Ganon L, Sela BA, Bahat H, Goldman M, Weissgarten J, Millar MR, Wright AF, Holtzman EJ. Homozygous SLC2A9 mutations cause severe renal hypouricemia. J. Am. Soc. Nephrol., 21, 64-72 (2010).
7. Bahn A, Hagos Y, Reuter S, Balen D, Brzica H, Krick W, Burckhardt BC, Sabolic I, Burckhardt G. Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J. Biol. Chem., 283, 16332-16341 (2008).
8. Yamauchi T, Ueda T. Primary hyperuricemia due to decreased renal uric acid excretion. Nihon Rinsho, 66, 679-681 (2008).
9. Kimura T, Amonpatumrat S, Tsukada A, Fukutomi T, Jutabha P, Thammapratip T, Lee EJ, Ichida K, Anzai N, Sakurai H. Increased expression of SLC2A9 decreases urate excretion from the kidney. Nucleosides Nucleotides Nucleic Acids, 30, 1295-1301 (2011).
10. Anzai N, Miyazaki H, Noshiro R, Khamdang S, Chairoungdua A, Shin HJ, Enomoto A, Sakamoto S, Hirata T, Tomita K, Kanai Y, Endou H. The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus. J. Biol. Chem., 279, 45942-45950 (2004).
11. Chaichian Y, Chohan S, Becker MA. Long-term management of gout: nonpharmacologic and pharmacologic therapies. Rheum. Dis. Clin. North Am., 40, 357-374 (2014).
12. Niu Y, Lu W, Gao L, Lin H, Liu X, Li L. Reducing effect of mangiferin on serum uric acid levels in mice. Pharm. Biol., 50, 1177-1182 (2012).
13. Ge DD, Zhang Y, Liu EW, Wang T, Hu LM. Chemical constituents of Mangifera indica leaves. Chin. Tradit. Herbal Drugs, 42, 428-431 (2011).
14. Pan Y, Chu Z, Wang W, Yang B. Pretreatment with Jieduxiezhuo decoction impedes elevations in serum uric acid levels in mice. J. Tradit. Chin. Med., 33, 794-797 (2013).
15. Carroll JJ, Coburn H, Douglass R, Babson AL. A simplified alkaline phosphotungstate assay for uric acid in serum. Clin. Chem., 17, 158-160 (1971).
16. Yu Z, Fong WP, Cheng CH. The dual actions of morin (3,5,7,2′,4′-pentahydroxyflavone) as a hypouricemic agent: uricosuric effect and xanthine oxidase inhibitory activity. J. Pharmacol. Exp. Ther., 316, 169-175 (2006).
17. Li JM, Zhang X, Wang X, Xie YC, Kong LD. Protective effects of cortex fraxini coumarines against oxonate-induced hyperuricemia and renal dysfunction in mice. Eur. J. Pharmacol., 666, 196-204 (2011).
18. Hu QH, Zhang X, Wang Y, Kong LD. Mangiferin promotes uric acid excretion and kidney function improvement and modulates related renal transporters in hyperuricemic mice. Yao Xue Xue Bao, 45, 1239-1246 (2010).
19. Pascual E, Perdiguero M. Gout, diuretics and the kidney. Ann. Rheum. Dis., 65, 981-982 (2006).
20. Pelis RM, Wright SH. SLC22, SLC44, and SLC47 transporters-organic anion and cation transporters: molecular and cellular properties. Curr. Top. Membr., 73, 233-261 (2014).
21. Shin HJ, Takeda M, Enomoto A, Fujimura M, Miyazaki H, Anzai N, Endou H. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrology, 16, 156-162 (2011).
22. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, Sakurai H. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J. Biol. Chem., 283, 26834-26838 (2008).
23. Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J. Am. Soc. Nephrol., 18, 430-439 (2007).
24. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H, EUROSPAN Consortium, Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI, ENGAGE Consortium, Meitinger T, Mooser V, Munroe P, Nauck M, Peden J, Prokisch H, Salo P, Salomaa V, Samani NJ, Schlessinger D, Uda M, Völker U, Waeber G, Waterworth D, Wang-Sattler R, Wright AF, Adamski J, Whitfield JB, Gyllensten U, Wilson JF, Rudan I, Pramstaller P, Watkins H, PROCARDIS Consortium, Doering A, Wichmann HE, KORA Study, Spector TD, Peltonen L, Völzke H, Nagaraja R, Vollenweider P, Caulfield M, WTCCC, Illig T, Gieger C. Meta-analysis of 28141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet., 5, e1000504 (2009).
25. Miyazaki H, Anzai N, Ekaratanawong S, Sakata T, Shin HJ, Jutabha P, Hirata T, He X, Nonoguchi H, Tomita K, Kanai Y, Endou H. Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins. J. Am. Soc. Nephrol., 16, 3498-3506 (2005).
26. Mount DB. The kidney in hyperuricemia and gout. Curr. Opin. Nephrol. Hypertens., 22, 216-223 (2013).
27. Sorensen LB. Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum., 8, 694-706 (1965).
28. Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl. Acad. Sci. U.S.A., 106, 10338-10342 (2009).
29. Hosomi A, Nakanishi T, Fujita T, Tamai I. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS ONE, 7, e30456 (2012).
30. Preitner F, Laverriere-Loss A, Metref S, Da Costa A, Moret C, Rotman S, Bazin D, Daudon M, Sandt C, Dessombz A, Thorens B. Dessombz Arnaud, Thorens B. Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice. Am. J. Physiol. Renal Physiol., 305, F786-F795 (2013).
31. Preitner F, Bonny O, Laverriére A, Rotman S, Firsov D, Da Costa A, Metref S, Thorens B. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc. Natl. Acad. Sci. U.S.A., 106, 15501-15506 (2009).